Table 4 Clinical and pathological characteristics of 10 patients with primitive monocytic sarcoma
Case | Age | Sex | Site | Primary/secondary or concurrent leukemia | Bone marrow | Immunohistochemistry | Treatment | Genetic testing | Recurrence (months) | Survival (months) | Reference | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | |||||||||||
1 | 21 | F | Intralesional | Combined leukemia | Abnormal cells 41.43% | CD45, CD117, Lysozyme, CD68, CD43, CD99(Localized+) | Mpo, CD4, Kappa, Lambda, CD3, CD20, CD138, CK, EMA, synaptophysin, GFAP, Vimentin | Refused chemo. | NA | 4 | NA | [3] |
2 | 28 | M | Intralesional | Primary | Primary and immature monocytes accounted for 5.50% | CD45, CD43, CD117(±), CD68, Lysozyme, CD99(Localized+), CD4(±) | Mpo, CD34, CD3, CD2, CD23, CD1a, AACT, CK, synaptophysin | Chemo. | NA | 15 | NA | [3] |
3 | 13 | M | Left alveolar, gingival | Primary | Three lines hyperplasia | CD68(KP-1), Lysozyme, CD117, Ki-67(60%) | MPO, CD34, LCA, CD20, CD45RO, TdT, CD99, CD138, CD56, S-100, synaptophysin, myoglobin | Chemo. (DA regimen) | NA | NA | 5 | [4] |
4 | 33 | M | External acoustic meatus | Secondary to leukemia | Three lines are normal | CD68(KP-1), Lysozyme, MPO(−/+), CD34, Ki-67(50%) | CD117, LCA, CD20, CD45RO, TdT, CD99, CD138, CD56, S-100, synaptophysin, myoglobin | Chemo. (DA regimen) | NA | NA | NA | [4] |
5 | 62 | M | Right upper arm | NA | NA | Vim, LCA, CD43, CD68, CD34, S-100, CD99 | CK, MPO, HMB45, Melan-A, EMA | NA | NA | NA | NA | [5] |
6 | 46 | M | Peritoneum | Leukemia | NA | CD68, CD56, CD45, CD4, NPM, LCA | AE1/3, EMA, calreticulin, CD117, synaptophysin, CGA, MPO, CD123, PS100 | Chemo. (cytarabine and idarubicin) | NA | NA | NA | [6] |
7 | 21 | M | Bilateral cervical lymph nodes | NA | NA | CD11C, CD14, CD43, CD68R | NA | Radio. | FIP1L1- PDGFRA rearrangement | NA | NA | [7] |
8 | 4 m | NA | Skin | NA | 0.245 for primary monocytes and juvenile monocytes | S-100, CD68, CD4, CD56, CD123, CD163, Ki-67(40%) | CD1, CD21, MPO | NA | NA | NA | 10 | [8] |
9 | 49 | F | Uterus | Leukemia | NA | CD15, CD43, CD45, CD68, Lysozyme, Ki-67(70%) | CD3, CD5, CD10, CD20, CD34, CD79a, CD117, CK, TdT, MPO | Chemo. (cytarabine and idarubicin) | MLL gene rearrangement | NA | NA | [9] |
10 | 2 | M | Lower jaw | Primary | No abnormalities | CD45, CD68, Lysozyme | CD3, CD20, CD99, TdT, MPO, CD138 | Chemo. (cytarabine and anthracyclines) | NA | NA | NA | [10] |